3rd Quarter - Report
ZIRKELBACH STRATEGIES for AMAG PHARMACEUTICALS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Client
Income
$45,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Nov 15, 2022 | $45,000 | Replaced |
| 3rd Quarter - Report | Nov 15, 2022 | $45,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pharmaceutical issues related to womens health product access and education on the accelerated approval pathway
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY KATHLEEN ZIRKELBACH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.